Can imatinib/Gleevec be used in combination with other medicines?
Imatinib/Gleevec (Imatinib) is an important targeted drug for the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). It is often used as a monotherapy, but in some cases it can also be used in combination with other drugs to enhance efficacy or overcome drug resistance. However, coadministration requires careful consideration of drug-drug interactions to ensure safety and efficacy.
InCML treatment, imatinib can be used in combination with interferon alpha or hematopoietic growth factors (such as G-CSF) to improve efficacy, especially in patients in the early chronic phase. This combination regimen has shown higher response rates and longer-lasting treatment effects in some patients. However, since imatinib has become the standard of care for CML, monotherapy is usually sufficient to control the disease, and combination with interferon alfa is less commonly used.

In addition, patients with imatinib-resistant CML may need to be combined with second- or third-generation tyrosine kinase inhibitors (TKIs) such as dasatinib or nilotinib, but this combination needs to be strictly managed under the guidance of a doctor to avoid excessive suppression of bone marrow hematopoietic function.
InGIST treatment, imatinib is mainly used for patients with KIT or PDGFRA mutations. When tumors become resistant to imatinib, it may be necessary to combine or switch to other TKIs such as sunitinib or regorafenib. However, this type of combination therapy is highly toxic and is only suitable for patients with advanced disease. In addition, some studies have explored the combination of imatinib and chemotherapy drugs, but due to limited efficacy, it has not yet become a standard treatment option. In general, although imatinib can be used in combination with other drugs, the specific regimen should be determined by the doctor after evaluating the patient's condition, drug resistance, and individual tolerance.
Reference materials:https://www.gleevec.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)